Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19CAR-TCM cells for CD19+ malignancies after HCT
NCT01475058Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Apr 2012
- Primary completion
- Apr 2014
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CD19CAR-TCM cells in acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), B cell lymphoma, sponsored by Fred Hutchinson Cancer Center. Started Apr 2012; status: completed.
02
Drugs
CD19CAR-TCM cells
03
Conditions
acute lymphoblastic leukemia (ALL)diffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)chronic lymphocytic leukemia (CLL)B cell lymphoma
Beyond the preview
Go deeper on NCT01475058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01475058.